Designed Liquid Crystalline Nanoassemblies From Clinically Validated Polyunsaturated Lipids for Combined Antioxidant, Anti-Apoptotic, and Neurotrophic Treatments.

Adv Healthc Mater · 2026 · PMC13241476 · PMID 41937329

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Although no significant difference was found between the other LNP treatments, we observed an increasing trend in ORAC activity compared to the LPS control, which highlighted the potential of our MO‐DLin LNPs as anti‐ROS agents.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.